IDEXX Laboratories, Inc.
General ticker "IDXX" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $48.6B (TTM average)
IDEXX Laboratories, Inc. follows the US Stock Market performance with the rate: 30.5%.
Estimated limits based on current volatility of 1.3%: low 552.14$, high 566.65$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Total employees count: 11000 (0.0%) as of 2025
- US accounted for 65.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Supply chain disruptions, Cybersecurity threats, Regulatory and compliance, Labor/talent shortage/retention
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [606.26$, 818.22$]
- 2026-12-31 to 2027-12-31 estimated range: [669.88$, 891.96$]
Financial Metrics affecting the IDXX estimates:
- Negative: with PPE of 52.8 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 31.60 > 18.39
- Positive: Inventory ratio change, % of -0.83 <= -0.75
- Positive: Investing cash flow per share per price, % of -0.25 > -0.60
- Positive: Return on assets ratio (scaled to [-100,100]) of 24.02 > 6.06
- Positive: Interest expense per share per price, % of 0.07 <= 0.73
- Positive: Industry inventory ratio change (median), % of 0 <= 0.28
- Positive: 42.59 < Shareholder equity ratio, % of 47.91 <= 64.29
- Positive: -0.02 < Operating cash flow per share per price, % of 2.14
Short-term IDXX quotes
Long-term IDXX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $3,660.95MM | $3,897.50MM | $4,303.70MM |
| Operating Expenses | $2,563.82MM | $2,769.17MM | $2,943.67MM |
| Operating Income | $1,097.13MM | $1,128.34MM | $1,360.03MM |
| Non-Operating Income | $-35.95MM | $-18.51MM | $-35.84MM |
| Interest Expense | $41.58MM | $31.20MM | $38.85MM |
| R&D Expense | $190.95MM | $219.79MM | $251.21MM |
| Income(Loss) | $1,061.18MM | $1,109.83MM | $1,324.19MM |
| Taxes | $216.13MM | $221.96MM | $264.73MM |
| Net Income(Loss)* | $845.04MM | $887.87MM | $1,059.46MM |
| Stockholders Equity | $1,484.53MM | $1,595.31MM | $1,605.38MM |
| Inventory | $380.28MM | $381.88MM | $377.76MM |
| Assets | $3,259.93MM | $3,293.44MM | $3,350.76MM |
| Operating Cash Flow | $906.51MM | $929.00MM | $1,181.81MM |
| Capital expenditure | $133.63MM | $130.92MM | $124.68MM |
| Investing Cash Flow | $-125.25MM | $-207.06MM | $-136.24MM |
| Financing Cash Flow | $-442.00MM | $-878.07MM | $-1,164.96MM |
| Earnings Per Share** | $10.17 | $10.77 | $13.23 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.